老年局部晚期头颈癌根治性放疗方案趋势与疗效:德国癌症注册组人群分析
基于德国癌症注册数据回顾分析84,046例头颈鳞癌患者(2000–2022年),评估≤70岁与>70岁患者根治性放疗方案趋势及生存结局。老年患者接受根治性放疗比例随时间显著增加,铂类放化疗仍最常用但>70岁使用率低于年轻组(26% vs 57%,P<0.001)。铂类放化疗5年OS在年龄组间可比(HR 1.01,P=0.83),而西妥昔单抗联合放疗(RT-Cet)较铂类放化疗OS更差且LRR更高,>70岁者负向影响更强。
要点
- 铂类放化疗是老年局部晚期HNSCC最有效方案,>70岁与≤70岁5年OS可比。
- RT-Cet较铂类放化疗OS更差、LRR更高,>70岁者负向影响更强。
- >70岁患者铂类放化疗使用率显著低于年轻患者(26% vs 57%)。
核心结论
- 铂类放化疗仍是老年局部晚期HNSCC最有效治疗,RT-Cet尤其>70岁者结局更差。
研究设计与样本
- 德国癌症注册组2000–2022年84,046例HNSCC回顾性分析,比较≤70岁与>70岁放疗方案趋势及OS、LRR。
主要发现
- 老年患者接受根治性放疗比例随时间显著增加。
- 铂类放化疗5年OS在≤70岁与>70岁组可比(HR 1.01,P=0.83)。
- RT-Cet较铂类放化疗OS更差(>70岁HR 2.31,P<0.001;≤70岁HR 1.55,P<0.001)。
- RT-Cet较铂类放化疗LRR更高(>70岁HR 2.11,P=0.003;≤70岁HR 1.43,P=0.002)。
- 单纯放疗未见上述年龄相关差异。
关键数值与推荐
- >70岁患者铂类放化疗使用率26%,≤70岁为57%(P<0.001)。
临床怎么用
- 老年局部晚期HNSCC应优先考虑铂类放化疗而非RT-Cet,尤其>70岁患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With increasing life expectancy, the number of elderly patients diagnosed with locally advanced head and neck squamous cell carcinoma (HNSCC) is rising. The effectiveness of definitive radiotherapy (RT) regimens in this population remains unclear. This study investigates RT regimen trends and their impact on overall survival (OS) and locoregional recurrence (LRR) in elderly HNSCC patients using a large German cancer registry dataset. METHODS: A retrospective analysis of 84,046 HNSCC cases from 2000 to 2022 was conducted. RT administration trends were assessed in patients aged ≤ 70 years and > 70 years. OS and LRR were analyzed in patients receiving definitive RT alone or combined with chemotherapy (RCTx) or cetuximab (RT-Cet), using Kaplan-Meier estimates and multivariate Cox regression models. RESULTS: The proportion of elderly patients receiving definitive RT regimens increased significantly over time. Platinum-based RCTx remained the most frequently used regimen but was less common in patients > 70 years than in younger patients (26 % vs. 57 %, P < 0.001). Five-year OS following platinum-based RCTx was comparable between age groups (HR 1.01, P = 0.83). In contrast, RT-Cet was associated with significantly worse OS and higher LRR compared to platinum-based RCTx, with a stronger negative impact in patients > 70 years (OS: HR 2.31, P < 0.001; LRR: HR 2.11, P = 0.003) than ≤ 70 years (OS: HR 1.55 P < 0.001; LRR: HR 1.43, P = 0.002). This age-related difference was not observed with RT alone. CONCLUSIONS: Platinum-based RCTx remains the most effective treatment for elderly HNSCC patients. RT-Cet is associated with poorer outcome particularly in patients > 70 years, underscoring the need for age-adapted, biology-informed treatment strategies.
引用
- Tinhofer I, Hofmann E, Trelinska-Finger A, et al. Trends and efficacy of definitive radiotherapy regimens for locally advanced head and neck cancer in elderly patients: A population-based analysis by the German cancer registry group. Eur J Cancer. 2025. PMID: 41056787. doi:10.1016/j.ejca.2025.116039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。